Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Am J Transplant. 2014 Aug 4;14(9):2173–2180. doi: 10.1111/ajt.12799

Figure 4. AZD8055 prolongs allograft survival and enhances graft-infiltrating Treg.

Figure 4

(A) The protocol for AZD8055 or RAPA administration following heart transplantation is depicted graphically. (B) B6 recipients of BALB/c heterotopic heart grafts were treated with AZD8055 (10 mg/kg twice daily i.p. from day 2-day 11) or RAPA (2 mg/kg loading dose on day 0 followed by 1 mg/kg/day i.p. from day 1–9) and allograft survival determined. The numbers of mice per group are shown in parentheses. (C) H&E staining of cardiac allografts was performed on day 10–11 following transplantation; bar indicates 200 μm. n=3 mice per group. (D) Foxp3+ cells in the allograft were identified by immunoperoxidase staining; bar indicates 100 μm and (E) quantified. (F) Foxp3 message in the allografts was determined by PCR. ns = not significant; * p<0.05; *** p<0.001 compared with the control group (no immunosuppression [IS]).